[Clinical evaluation of CA-50 in cases with colorectal cancer].

Osamu Nishida(Fujita Health University), Junji Uchino(Hokkaido University), Kunio Ohmori, Yuki Nakajima(Fujisawa City Hospital), Yukihiro Kondoh, Y Sawaguchi, K. Manabe(High Energy Accelerator Research Organization), Hiroshi Shiroto, Nobunori Satoh, Fuminori Sano

PubMed

April 1, 1989

Cited by 0

Related Papers

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

|Intensive Care Medicine|2017|6.8k

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

|Critical Care Medicine|2017|3.8k

Post-Intensive Care Syndrome and Its New Challenges in Coronavirus Disease 2019 (COVID-19) Pandemic: A Review of Recent Advances and Perspectives

|Journal of Clinical Medicine|2021|91

Nucleosides and nucleotides. 100. 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabinofuranosylcytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside

|Journal of Medicinal Chemistry|1991|85

ABCDEF Bundle and Supportive ICU Practices for Patients With Coronavirus Disease 2019 Infection: An International Point Prevalence Study

|Critical Care Explorations|2021|72